CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.8

ph-index = 9

Forward Citations = 212(Granted Patents)

Location History:

Beerse, BE (2016 - 2019)
Geel, BE (1998 - 2023)

Company Filing History:

7 out of 43

N.v. Innogenetics S.a.

patents

4 out of 410

Janssen Biotech, Inc.

patents

3 out of 2,076

Janssen Pharmaceutica Nv

Years Active: 1998-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11673943 - Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof (2023-06-13),

2. 10851156 - Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies (2020-12-01),

3. 10519223 - Antibodies to pyroglutamate amyloid-β and uses thereof (2019-12-31),

4. 10196440 - Anti-PHG-tau antibodies and their uses (2019-02-05),

5. 10000559 - Anti-PHF-tau antibodies and their uses (2018-06-19),

6. 9745371 - Anti-PHF-tau antibodies and their uses (2017-08-29),

7. 9371376 - Anti-PHF-tau antibodies and their uses (2016-06-21),

8. 8163873 - Isolated microtubule-associated protein tau peptides and kit (2012-04-24),

9. 6900293 - Monoclonal antibodies directed against the microtubule-associated protein tau (2005-05-31),

10. 6500674 - Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications (2002-12-31),

11. 6238892 - Monoclonal antibodies directed against the microtubule-associated protein tau (2001-05-29),

12. 6232437 - Isolated human tau peptide epitope which specifically binds monoclonal antibody AT120. (2001-05-15),

13. 6010913 - Isolated human tau peptide (2000-01-04),

14. 6008024 - Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, (1999-12-28),

15. 5861257 - Monoclonal antibodies directed against the microtubule-associated (1999-01-19),

Title: Marc Vandermeeren: Innovator in Alzheimer's Disease Research

Introduction

Marc Vandermeeren is a prominent inventor based in Geel, Belgium. He has made significant contributions to the field of Alzheimer's disease research, holding a total of 16 patents. His work focuses on innovative methods for diagnosing and treating conditions related to amyloid beta proteins.

Latest Patents

Among his latest patents are groundbreaking inventions that address the binding of amyloid beta protein with pyroglutamate at the third amino acid residue. One notable patent describes methods of binding this protein in vivo using anti-3pE abeta antibodies or their antigen-binding fragments. This invention provides valuable tools for the diagnosis, prognosis, and treatment of Alzheimer's disease and other beta-amyloid-related diseases. Another patent outlines methods for detecting pyroglutamate amyloid beta protein using these same antibodies, further enhancing the potential for effective therapeutic interventions.

Career Highlights

Throughout his career, Marc Vandermeeren has worked with notable companies such as N.V. Innogenetics S.A. and Janssen Biotech, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to Alzheimer's research.

Collaborations

Marc has collaborated with esteemed colleagues, including Marc Mercken and Eugeen Vanmechelen. These partnerships have contributed to the advancement of research in the field and have fostered a collaborative environment for innovation.

Conclusion

Marc Vandermeeren's contributions to Alzheimer's disease research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in diagnosis and treatment options for this challenging condition.

This text is generated by artificial intelligence and may not be accurate.